Cision Newshttps://news.cision.comCision is the leading global provider of media research, distribution, monitoring and evaluation services. With over 40 locations throughout the world, Cision provides the insight, expertise and intelligence that improve performance and build reputations.Tue, 09 Jun 2026 13:00:42 GMTCision News14660https://news.cision.comhttps://news.cision.com/Content/img/news-logo.pngAdmission of Further Securities to Tradinghttps://news.cision.com/astrazeneca/r/admission-of-further-securities-to-trading,c4355941cision5374658Mon, 01 Jun 2026 14:05:00 GMTTotal Voting Rightshttps://news.cision.com/astrazeneca/r/total-voting-rights,c4355955cision5374649Mon, 01 Jun 2026 14:00:00 GMTImfinzi approved in US for early bladder cancerhttps://news.cision.com/astrazeneca/r/imfinzi-approved-in-us-for-early-bladder-cancer,c4354945cision5373021Fri, 29 May 2026 06:00:00 GMTUS FDA decision date on camizestrant extendedhttps://news.cision.com/astrazeneca/r/us-fda-decision-date-on-camizestrant-extended,c4353645cision5370934Wed, 27 May 2026 06:00:00 GMTDatroway approved in US for 1L triple-negative BChttps://news.cision.com/astrazeneca/r/datroway-approved-in-us-for-1l-triple-negative-bc,c4352964cision5369792Tue, 26 May 2026 06:00:00 GMTEnhertu recommended in EU for HER2+ solid tumourshttps://news.cision.com/astrazeneca/r/enhertu-recommended-in-eu-for-her2--solid-tumours,c4352965cision5369794Tue, 26 May 2026 06:00:00 GMTCamizestrant recommended for breast cancer in EUhttps://news.cision.com/astrazeneca/r/camizestrant-recommended-for-breast-cancer-in-eu,c4352967cision5369796Tue, 26 May 2026 06:00:00 GMTDirector/PDMR Shareholdinghttps://news.cision.com/astrazeneca/r/director-pdmr-shareholding,c4349603cision5364861Mon, 18 May 2026 14:00:00 GMTEnhertu approved in two HER2+ early BC settingshttps://news.cision.com/astrazeneca/r/enhertu-approved-in-two-her2--early-bc-settings,c4349368cision5364208Mon, 18 May 2026 06:05:00 GMTBaxfendy approved in the US for hypertensionhttps://news.cision.com/astrazeneca/r/baxfendy-approved-in-the-us-for-hypertension,c4349370cision5364181Mon, 18 May 2026 06:00:00 GMTImfinzi + EV improves EFS & OS in bladder cancerhttps://news.cision.com/astrazeneca/r/imfinzi---ev-improves-efs---os-in-bladder-cancer,c4348672cision5363288Thu, 14 May 2026 06:00:00 GMTTotal Voting Rights and Admission of Shareshttps://news.cision.com/astrazeneca/r/total-voting-rights-and-admission-of-shares,c4343483cision5355344Fri, 01 May 2026 14:00:00 GMTFDA ODAC vote on camizestrant in breast cancerhttps://news.cision.com/astrazeneca/r/fda-odac-vote-on-camizestrant-in-breast-cancer,c4343408cision5355179Fri, 01 May 2026 06:05:00 GMTFDA ODAC recommends Truqap in prostate cancerhttps://news.cision.com/astrazeneca/r/fda-odac-recommends-truqap-in-prostate-cancer,c4343405cision5355170Fri, 01 May 2026 06:00:00 GMT1st Quarter Resultshttps://news.cision.com/astrazeneca/r/1st-quarter-results,c4341878cision5352975Wed, 29 Apr 2026 06:00:00 GMTBreztri approved in the US for asthmahttps://news.cision.com/astrazeneca/r/breztri-approved-in-the-us-for-asthma,c4341023cision5351727Tue, 28 Apr 2026 06:27:26 GMTSaphnelo self-administration approved in the UShttps://news.cision.com/astrazeneca/r/saphnelo-self-administration-approved-in-the-us,c4340319cision5350690Mon, 27 Apr 2026 06:00:00 GMTDirectorate changehttps://news.cision.com/astrazeneca/r/directorate-change,c4338932cision5348606Thu, 23 Apr 2026 06:00:00 GMTI CAN PhIII interim analysis met primary endpointhttps://news.cision.com/astrazeneca/r/i-can-phiii-interim-analysis-met-primary-endpoint,c4337443cision5346467Tue, 21 Apr 2026 06:00:00 GMTThird tozorakimab positive Phase III in COPDhttps://news.cision.com/astrazeneca/r/third-tozorakimab-positive-phase-iii-in-copd,c4336841cision5345689Mon, 20 Apr 2026 06:00:00 GMTResult of AGMhttps://news.cision.com/astrazeneca/r/result-of-agm,c4332902cision5340242Thu, 09 Apr 2026 16:25:12 GMTImfinzi+Imjudo improves PFS in early liver cancerhttps://news.cision.com/astrazeneca/r/imfinzi-imjudo-improves-pfs-in-early-liver-cancer,c4330517cision5336946Thu, 02 Apr 2026 06:21:24 GMTTotal Voting Rights and Admission of Shareshttps://news.cision.com/astrazeneca/r/total-voting-rights-and-admission-of-shares,c4329740cision5336584Wed, 01 Apr 2026 14:00:00 GMTEfzimfotase alfa Ph3 program show positive resultshttps://news.cision.com/astrazeneca/r/efzimfotase-alfa-ph3-program-show-positive-results,c4329064cision5334708Tue, 31 Mar 2026 06:00:00 GMT